指南与共识银屑病与炎症性皮肤病皮肤肿瘤

度普利尤单抗治疗特应性皮炎相关皮肤T细胞淋巴瘤:系统综述与专家共识

Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2026-03-12

该系统综述纳入51项研究报告度普利尤单抗治疗后出现皮肤T细胞淋巴瘤(CTCL)的病例,共547例患者(平均年龄58岁),随后通过改良德尔菲法形成专家共识。结果显示度普利尤单抗可能揭示或加重既存CTCL,尤其蕈样肉芽肿(MF)和Sézary综合征,专家建议对40岁后发病或非典型表现者保持诊断警惕,确诊CTCL后应停用度普利尤单抗。

要点

  • 度普利尤单抗可能揭示或加重既存CTCL,尤其是MF和Sézary综合征。
  • AD患者40岁后发病或具非典型特征时,应警惕CTCL并进行皮肤活检等检查。
  • 确诊CTCL后应停用度普利尤单抗,可考虑甲氨蝶呤或光疗作为替代。

核心结论

  • 度普利尤单抗可能揭示或加重CTCL,尤其是MF和Sézary综合征。
  • 专家共识为CTCL相关情境下安全使用度普利尤单抗提供了实践指导。

研究设计与样本

  • 系统综述纳入51项研究报告度普利尤单抗治疗患者中出现CTCL的病例,随后采用改良德尔菲法形成专家共识推荐。

主要发现

  • 共获得547例患者数据,平均年龄58岁(SD 11.5,范围10-85)。
  • 度普利尤单抗起始后出现新发或加重皮损的平均时间为8.9个月(SD 5.1,范围0.5-27个月)。
  • 诊断为MF者占72%,Sézary综合征占11%,其他CTCL亚型占19%,其中53%为早期(≤IIA期)。
  • 75%的病例停用度普利尤单抗,62%接受了CTCL导向治疗。
  • 在63例有随访数据的患者中,44例达到临床缓解。

关键数值与推荐

  • 专家小组广泛共识:度普利尤单抗可能揭示或加重既存CTCL,应避免用于MF/Sézary综合征及mogamulizumab诱导的皮疹。
  • 强调诊断警惕性,建议在治疗前和治疗中行皮肤活检、组织学和克隆性检测,尤其对40岁后发病或具非典型特征的AD患者。
  • 确诊CTCL后应停用度普利尤单抗,考虑甲氨蝶呤或光疗作为替代。
  • 环孢素和JAK抑制剂被认为不适合,因数据不足不鼓励换用其他Th2靶向生物制剂。

临床怎么用

  • 对40岁后发病或具非典型特征的AD患者,在度普利尤单抗治疗前和治疗中应行皮肤活检、组织学和克隆性检测。
  • 确诊CTCL后应停用度普利尤单抗,可考虑甲氨蝶呤或光疗作为替代方案。
  • 避免将度普利尤单抗用于MF/Sézary综合征及mogamulizumab诱导的皮疹。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Dupilumab, a standard treatment for atopic dermatitis (AD), has been associated with cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF) and Sézary syndrome (SS). Nevertheless, the available data remain heterogeneous. OBJECTIVES: To characterize the clinical features, timeline and outcomes of dupilumab-related CTCL emergence in order to develop consensus-based recommendations for dupilumab use in CTCL-related settings. METHODS: A systematic review was conducted involving 51 studies reporting cases of CTCL in patients treated with dupilumab, followed by a modified delphi process to generate expert consensus recommendations. RESULTS: Data were obtained from 547 patients (mean age: 58 years; SD: 11.5; range: 10-85). New or worsening skin lesions were reported after dupilumab initiation, occurring at a mean of 8.9 months (SD 5.1; range 0.5-27 months). These were diagnosed as MF in 72% of cases, SS in 11% and other CTCL subtypes in 19%, of which 53% were at an early stage (stage ≤IIA). Dupilumab was discontinued in 75% of cases, and 62% received CTCL-directed treatment. Clinical remission was achieved in 44 of the 63 patients with available follow-up. The expert panel reached broad consensus, agreeing that dupilumab may unmask or exacerbate pre-existing CTCL and should be avoided in cases of MF/SS and mogamulizumab-induced rashes. They emphasized the importance of diagnostic vigilance, providing recommendations for skin biopsy, histology and clonality testing before and during treatment, particularly for patients with AD onset after the age of 40 or with atypical features. Dupilumab should be discontinued once CTCL confirmed, and methotrexate or phototherapy considered as alternatives. Cyclosporine and JAK inhibitors are considered unsuitable, and switching to other Th2-targeting biologics is discouraged due to insufficient data. CONCLUSIONS: Dupilumab may unmask or exacerbate CTCL, particularly MF and SS. The consensus-based recommendations offer practical guidance for the safe management of patients.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Amatore F, Neildez M, de Masson A, et al. Cutaneous T-cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus. J Eur Acad Dermatol Venereol. 2026. PMID: 41821352. doi:10.1111/jdv.70407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。